The Dow Jones Industrials (DJINDICES: ^DJI ) have put in extraordinarily strong performance so far this year, rising about 15% in 2013. What many U.S. investors don't realize, though, is how much the Dow has outperformed more global benchmarks of stock markets around the world.
Get to know the Global Dow
The Dow includes 30 of the most influential U.S. companies in the global economy. But if you want to get an even better measure of how the world stock market is performing, then turning to the Global Dow gives you a broader perspective. The Global Dow includes 150 stocks, each of which gets equal weight rather than price-based weighting. You'll find all 30 of the Dow Industrials in the Global Dow, along with some of the stocks that show up in the Dow's Transportation and Utility Averages as well.
With so many of the U.S. Dow averages' components, it's not surprising that U.S. stocks make up 42% of the overall Global Dow. But Japan represents about 10% of the average, and countries in Europe together compose more than 30%.
10 Best Gas Utility Stocks To Invest In 2015: Petroquest Energy Inc(PQ)
PetroQuest Energy, Inc. operates as an independent oil and gas company. It engages in the acquisition, exploration, development, and operation of oil and gas properties in Oklahoma, Arkansas, and Texas, as well as onshore and in the shallow waters offshore the Gulf Coast Basin. As of December 31, 2009, the company had estimated proved reserves of 1,931 thousand barrels of oil and 167,361 million cubic feet equivalent of natural gas. It owned working interests in 9 net producing oil wells and 277 net producing gas wells. PetroQuest Energy was founded in 1983 and is headquartered in Lafayette, Louisiana.
Advisors' Opinion:- [By Jon C. Ogg]
PetroQuest Energy Inc. (NYSE: PQ) was downgraded to Neutral from Overweight at J.P. Morgan.
Rubicon Technology Inc. (NASDAQ: RBCN) was downgraded to Underperform from Perform at Oppenheimer.
Top Performing Stocks To Own Right Now: Synergy Pharmaceuticals Inc (SGYP)
Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.
As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.
The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.
Advisors' Opinion:- [By Sean Williams]
Finally, Synergy Pharmaceuticals (NASDAQ: SGYP ) may have had the wildest week of them all. Synergy's share price spiked 16% on Tuesday as an analyst at Cantor Fitzgerald raised her peak sales estimate for plecanatide, the company's midstage drug for chronic idiopathic constipation and irritable bowel syndrome with constipation, to $1.58 billion from $1.05 billion, as clinical data has been stronger than expected. However, the company didn't return the favor to shareholders by -- the very next day, mind you ��announcing a secondary offering of 16.375 million shares. The downside of clinical-stage companies is the always apparent risk of dilution. Shares have lost 25% since their Tuesday close.
- [By Monica Gerson]
Breaking news
Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Top Performing Stocks To Own Right Now: MEG Energy Corp (MEGEF.PK)
MEG Energy Corp. is a Canada-based oil sands company focused on in situ development and production in the southern Athabasca oil sands region of Alberta. The Company has identified two steam assisted gravity drainage projects, the Christina Lake project and the Surmont project. The Company owns a 100% interest in over 900 sections of oil sands leases in the Athabasca region of northern Alberta and is primarily engaged in a steam assisted gravity drainage oil sands development at its 80 section Christina Lake Regional Project (Christina Lake Project). The development includes co-ownership of Access Pipeline, a dual pipeline to transport diluent north from the Edmonton area to the Athabasca oil sands area and a blend of bitumen and diluent south from the Christina Lake Project into the Edmonton area. Advisors' Opinion:- [By Stephan Dube]
Athabasca's most notable producers:
Suncor Energy (SU) (Part 1), see article here.Suncor Energy (Part 2), see article here.Athabasca Oil (ATHOF.PK), see article here.Canadian Natural Resources, see article here.Imperial Oil, see article here.Cenovus Energy (CVE), see article here.MEG Energy (MEGEF.PK), see article here.Devon Energy, see article here.Royal Dutch Shell, see article here.Ivanhoe Energy (IVAN), see article here.Nexen (CNOOC) (CEO), see article here.An analysis of the current operations of the company will be examined with the objective to provide the most complete information available to potential investors before deciding to seize the opportunity that the 54,132 square miles of the Carbonate Triangle has to offer. Let's start by introducing Athabasca, a famous and most prolific region in the Canadian oil sands as well as one of the largest reserve in the world.
Top Performing Stocks To Own Right Now: Regis Corporation(RGS)
Regis Corporation owns, operates, and franchises hairstyling and hair care salons in the United States, the United Kingdom, Canada, Puerto Rico, and internationally. It offers haircutting and styling, including shampooing and conditioning; hair coloring; and waving to men, women, and children. The company also owns and operates hair restoration centers, which provide hair systems, hair transplants, and hair therapy services, as well as hair care products. Its salons operate primarily under the Regis Salons, MasterCuts, SmartStyle, Supercuts, Cost Cutters, Sassoon, Promenade salons, Hair Masters, First Choice Haircutters, Magicuts, and Hair Club trade names in regional shopping malls, strip centers, lifestyle centers, Wal-Mart supercenters, department stores, mass merchants, and high-street locations. As of June 30, 2011, the company owned, franchised, or held ownership interests in approximately 12,700 locations. Regis Corporation was founded in 1922 and is headquartered i n Edina, Minnesota.
Advisors' Opinion:- [By Geoff Gannon]
For example, a company involved in a mundane business like running hair salons ��like Regis (RGS), dentist offices ��like Birner Dental (BDMS), grocery stores ��like Village Supermarket (VLGEA), or garbage dumps ��like Waste Management (WM), may be easy to estimate as essentially a no-growth business.
Top Performing Stocks To Own Right Now: C.R. Bard Inc. (BCR)
C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company?s vascular products include percutaneous transluminal angioplasty catheters, chronic total occlusions catheters, guidewires, introducers, and accessories; peripheral vascular stents and stent grafts, vena cava filters, and biopsy devices; electrophysiology products, such as electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products comprise infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachyt herapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for ureteroscopic procedures and stone removal; and catheter stabilization devices. The company?s oncology products consist of specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation systems for hernia and other soft tissue repairs; irrigation devices for orthopedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. C. R. Bard sells its products directly and through distributors to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company was founded in 1907 and is based in Murray Hill, New Jersey.
Advisors' Opinion:- [By Jonas Elmerraji]
At least mid-cap medical device maker C.R. Bard (BCR) has been able to keep pace with the S&P this year. Bard makes medical consumables -- one-time-use products designed for an array of medical, surgical, and diagnostic uses. The firm's offerings include everything from biopsy needles and catheters to ultrasound systems.
It's the focus on the consumable side of the business, though, that's been fuelling Bard's top line in 2013. All together, consumables make up around 90 cents out of every dollar the firm earns -- and they come with deep margins and recurring orders as well. A rising tide should help to lift all ships in the medical device market; whatever you think about programs like Obamacare, the net result is more patients and higher rates of medical consumables used.
One of Bard's biggest selling points is preventative -- the firm's top-selling catheters, for instance, help to reduce the likelihood of patient infection, a complication that comes with astronomical costs for hospitals. That proprietary advantage gives Bard an edge in a device that otherwise appears pretty low-moat.
In my view, Bard is a good example of a strong middle-of-the-road health care name. It's certainly not the most exciting company in the sector (far from it), but it's worth owning for investors looking for health exposure in 2013. Institutions picked up 2.26 million shares of Bard, boosting their stakes by more than 20% in the last quarter.
No comments:
Post a Comment